Drugs News and Research

RSS

New research finds key proteins involved in the process of memory and learning

New research led by the University of Leicester and published in a prestigious international scientific journal has revealed for the first time the mechanism by which memories are formed.

28 Jun 2010

Linagliptin mono- and combination therapy improves blood glucose control

Linagliptin phase III data were presented for the first time this week at the 70th Scientific Sessions of the American Diabetes Association (ADA), showing that this investigational compound, a dipeptidyl peptidase (DPP)-4 inhibitor, achieved significant, sustained and clinically meaningful reductions in blood glucose as measured by haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and postprandial glucose (PPG) concentrations.(1-6) Linagliptin is being investigated by Boehringer Ingelheim as a once-daily oral treatment in type 2 diabetes.

28 Jun 2010

Loyola University Hospital awarded Joint Commission's certification as Advanced Primary Stroke Center

The Joint Commission has recertified Loyola University Hospital as an Advanced Primary Stroke Center.

28 Jun 2010

AHF rejects Obama trial balloon of $30M for nation's ADAP

AIDS Healthcare Foundation, the largest global AIDS organization, is rejecting a trial balloon floated by Obama Administration officials that suggests $30 million in additional funding could adequately help close a gaping $126 million hole in funding for the nation's AIDS Drug Assistance Program, the federal and state funded, state run network of assistance programs that supply lifesaving AIDS drugs to low-income Americans in need.

28 Jun 2010

EVISTA improves bone quality as measured by HRpQCT: IIT

Interim data from a prospective Investigator Initiated Trial presented today at the ECTS, the 37th European Symposium on Calcified Tissues, in Glasgow, demonstrates that EVISTA (raloxifene 60mg; once-daily, distributed in 34 countries by DAIICHI SANKYO), indicated for the treatment and prevention of osteoporosis in postmenopausal women, improves bone quality as measured by the high-resolution peripheral quantitative computed tomography.

28 Jun 2010

Data shows proportion of total sales from drugs dropped to below 7%

The pharmaceutical industry continues to rely heavily on sales from an aging portfolio of drugs, whilst the proportion of total sales from newer drugs has dropped, according to data released today from the 2010 Pharmaceutical R&D Factbook complied by CMR International, a Thomson Reuters business.

28 Jun 2010

WellPoint research leads to limits on use of Boniva; FDA spars with tobacco company

"WellPoint Inc. (WLP), the largest U.S. managed-care concern by membership, made it harder last year for its members to gain approval for use of the Boniva osteoporosis drug after internal research linked it to higher fracture rates, lower patient compliance and higher total costs of care than two other drugs, a WellPoint executive said Thursday," Dow Jones Newswires/The Wall Street Journal reports.

28 Jun 2010

TRL commences operations at San Diego facility with focus on biological drugs for autoimmune diseases

Tanabe Research Labs USA, Inc. (TRL) today announced commencement of its new operations at the TRL facility in San Diego with a focus on biological drugs for the treatment of autoimmune diseases. TRL began its new activities in May with the appointment of three new senior executives: Masaki Yamada, Ph.D., Chief Executive Officer; Toshihiro Hosaka, Ph.D., Senior Vice President, and Roland Newman, Ph.D., VP and Chief Scientific Officer.

28 Jun 2010

FDA grants orphan drug designation for Chiasma's Octreolin

Chiasma, Inc., a privately held biopharma company, announced that the Food and Drug Administration has granted orphan drug designation for Chiasma's investigational new drug, Octreolin, an oral form of octreotide acetate that uses the Company's proprietary Transient Permeability Enhancer technology for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.

28 Jun 2010

Mass. bill would lift gift ban; Workers rally in Md., Minn.

"A two-year-old state ban on gifts in the medical and pharmaceutical industries would be repealed under an economic development bill that the House budget committee began polling its members on yesterday. The ban, which prohibits drug firms from giving gifts and meals to health care professionals, has cut back on local business profits, a summary of the bill states. When it passed as part of a broader health care bill in 2008, supporters called it a way of curbing pharmaceutical companies' influence" (O'Sullivan, 6/25).

28 Jun 2010

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.

28 Jun 2010

Antioxidant therapy may prevent long-lasting cognitive impairment in cerebral malaria: Research

Using an experimental mouse model for malaria, an international group of scientists has discovered that adding antioxidant therapy to traditional antimalarial treatment may prevent long-lasting cognitive impairment in cerebral malaria. Their findings were published online June 24, 2010, in the journal PLoS Pathogens.

28 Jun 2010

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced data on ZGN-201, a prototype methionine aminopeptidase 2 inhibitor, for the treatment of obesity. Preclinical studies demonstrate MetAP2 inhibition eliminates excess body weight through the regulation of fat metabolism and food intake, and normalizes glucose tolerance in animal models.

28 Jun 2010

WCO signs declaration, vows to crack down on counterfeit drug industry

World Customs Organization Secretary General Kunio Mikuriya on Thursday signed a declaration vowing his group's commitment to crack down on the counterfeit drug industry, PBS NewsHour's "The Rundown" blog reports. The piece examines the growing threat of counterfeit medications worldwide and efforts to clamp down on the distribution of such drugs (Miller, 6/24).

28 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.

28 Jun 2010

Insurer sees coming health insurer 'oligopoly,' doctors band together on system changes

Bloomberg Businessweek reports that health insurer WellPoint's investor-relations chief said Thursday that health insurers are "moving towards an oligopoly" accelerated by the new law. "New regulations on administrative spending and premium increases will push some independent insurers out of business or into deals with bigger rivals, said Michael Kleinman, vice president for investor relations, at a Wells Fargo & Co. conference in Boston.

28 Jun 2010

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

The cause of diabetes during pregnancy is directly controlled by serotonin, a chemical produced by the body and normally known as a neurotransmitter, and is influenced by the amount of protein in the mother's diet early in pregnancy, according to new findings of an international team led by researchers at UCSF.

28 Jun 2010

Antiviral therapy prevents recurrence of HCC, extends patients' lives, researchers report

Previous studies have shown that antiviral treatment reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B. But now, researchers from the Division of Gastroenterology and Hepatology at Thomas Jefferson University are reporting that the antiviral therapy also prevents recurrence of HCC and extends patients' lives.

25 Jun 2010

Research roundup: Docs' views of industry gifts; Chemotherapy payments; Health law and states

How Medicare's Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment -- This study examines the impact that Medicare payment cuts for chemotherapy drugs had on treatment for Medicare beneficiaries with newly diagnosed lung cancer, before and after implementation of the June 2005 new payment system, focusing on five chemotherapy drugs "in common use singly or jointly for lung cancer..."

25 Jun 2010

Drugs News and Research

New research finds key proteins involved in the process of memory and learning

Linagliptin mono- and combination therapy improves blood glucose control

Loyola University Hospital awarded Joint Commission's certification as Advanced Primary Stroke Center

AHF rejects Obama trial balloon of $30M for nation's ADAP

EVISTA improves bone quality as measured by HRpQCT: IIT

Data shows proportion of total sales from drugs dropped to below 7%

WellPoint research leads to limits on use of Boniva; FDA spars with tobacco company

TRL commences operations at San Diego facility with focus on biological drugs for autoimmune diseases

FDA grants orphan drug designation for Chiasma's Octreolin

Mass. bill would lift gift ban; Workers rally in Md., Minn.

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Antioxidant therapy may prevent long-lasting cognitive impairment in cerebral malaria: Research

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

WCO signs declaration, vows to crack down on counterfeit drug industry

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Insurer sees coming health insurer 'oligopoly,' doctors band together on system changes

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

Antiviral therapy prevents recurrence of HCC, extends patients' lives, researchers report

Research roundup: Docs' views of industry gifts; Chemotherapy payments; Health law and states

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News